advexin: Clinical Trials

19 trials of advexin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 terminated, 4 unknown, 1 withdrawn. 11 Phase 1, 7 Phase 2, 2 Phase 3, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 111Completed 8, Terminated 3
Phase 27Completed 3, Terminated 2, Unknown 2
Phase 32Unknown 2
Not applicable1Withdrawn 1

Follow advexin: new trials by email Literature Review of advexin trials Research Report on advexin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Ad-P53, Xeloda, Keytruda - Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Phase 1 / Phase 2TerminatedMultiVir, Inc.42018-11-202020-06-02
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Ad-p53 - Solid Tumor, Lymphoma
Phase 2UnknownMultiVir, Inc.402018-10-012020-06-09
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
Adenovirus-p53 transduced dendritic cell vaccine, 1-methyl-D-tryptophan, Carbon C 11 alpha-methyltryptophan - Breast Cancer
Not applicableWithdrawnH. Lee Moffitt Cancer Center and Research Institute2013-01-012017-02-23
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Ad5CMV-p53 gene, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oropharyngeal Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)512003-06-012013-01-23
Wild Type p53 Adenovirus for Oral Premalignancies
INGN 201 - Mouth Cancer
Phase 1TerminatedM.D. Anderson Cancer Center42003-06-012011-12-07
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
Ad5CMV-p53 gene, cisplatin, conventional surgery - Head and Neck Cancer
Phase 2TerminatedSWOG Cancer Research Network132003-02-012012-06-14
Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride - Breast Cancer
Phase 2CompletedIntrogen Therapeutics2002-02-012013-05-30
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Ad5CMV-p53 gene, radiation therapy - Lung Cancer
Phase 1CompletedEastern Cooperative Oncology Group2000-01-012010-07-07
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Ad5CMV-p53 gene, conventional surgery - Brain and Central Nervous System Tumors
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins1999-02-252018-06-27
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Ad5CMV-p53 gene, chemotherapy - Breast Cancer
Phase 1CompletedNational Cancer Institute (NCI)201999-01-012013-02-07
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed
Ad5CMV-p53 gene - Lung Cancer
Phase 1CompletedEastern Cooperative Oncology Group1998-11-172023-06-22
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
Ad5CMV-p53 gene - Ovarian Cancer, Peritoneal Cavity Cancer
Phase 1CompletedUniversity of Texas Southwestern Medical Center1998-09-012021-02-02
Gene Therapy in Treating Patients With Ovarian Cancer
Ad5CMV-p53 gene, laparoscopic surgery - Ovarian Cancer
Phase 1CompletedNational Cancer Institute (NCI)301998-09-012013-02-08
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Ad5CMV-p53 gene - Recurrent Bladder Cancer, Stage I Bladder Cancer
Phase 1CompletedNational Cancer Institute (NCI)241998-05-012013-01-23
Gene Therapy in Treating Patients With Cancer of The Liver
Ad5CMV-p53 gene - Liver Cancer
Phase 1TerminatedNational Cancer Institute (NCI)301998-02-012013-02-05
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
Ad5CMV-p53 gene - Head and Neck Cancer
Phase 2UnknownAventis Pharmaceuticals391998-01-012013-12-04
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
INGN 201 - Carcinoma, Squamous Cell
Phase 3UnknownIntrogen Therapeutics2007-09-11
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
INGN 201 - Locally Advanced Breast Cancer (LABC)
Phase 2CompletedIntrogen Therapeutics602008-04-01
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
INGN 201 - Carcinoma, Squamous Cell
Phase 3UnknownIntrogen Therapeutics2008-04-01

Conditions studied

Squamous Cell Carcinoma of Head and Neck (4)  ·  Breast Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Head and Neck Neoplasms (3)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Carcinoma, Squamous Cell (2)  ·  Liver Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Mouth Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Ovarian Neoplasms (2)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms, Male (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Introgen Therapeutics (4)  ·  Eastern Cooperative Oncology Group (2)  ·  MultiVir, Inc. (2)  ·  Aventis Pharmaceuticals (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  M.D. Anderson Cancer Center (1)  ·  SWOG Cancer Research Network (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (18)

Top investigators

Julie L Sicam, MT (ASCP) MSHS (2)  ·  Kerstin Menander, MD (2)  ·  Carolyn Y. Muller, MD (1)  ·  Chandra P. Belani, MD (1)  ·  David P. Carbone, MD, PhD (1)  ·  Frederick F. Lang, MD (1)  ·  Gary L. Clayman (1)  ·  Gary L. Clayman, MD (1)  ·  George H. Yoo, MD (1)  ·  Hatem Soliman, M.D. (1)  ·  Jill Van Warthood, PhD (1)  ·  Joan H. Schiller, MD (1)  ·  Judith K. Wolf, MD (1)  ·  Lance Pagliaro (1)  ·  Lyndah Dreiling, MD (1)

Results publications

PMID 18757331, PMID 19770418

NIH funding

P50CA097007 (1), R21CA076233 (1), U10CA032102 (1)